Rubicon Research
add_icon

Rubicon Research

1,272.00
-30.60
(-2.35%)
Market Cap
20,956.20 Cr
PE Ratio
84.93
Volume
18,72,793.00
Day High - Low
1,338.80 - 1,260.40
52W High-Low
1,370.00 - 570.75
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
20,956.20 Cr
EPS
15.52
PE Ratio
84.93
PB Ratio
16.26
Book Value
78.23
EBITDA
400.24
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
24.84
Debt to Equity
0.91
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Rubicon Research Limited has released the audio recording of its Q4FY26 earnings conference call held on May 30, 2026. The recording is now available on the company's official website.
neutral
Rubicon Research approved ESOS 2026 for 24.84 lakh options. The scheme requires shareholder approval.
neutral
Rubicon Research Limited board meets on May 29, 2026, to consider FY26 audited results and dividend recommendation.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,788.50
#1 4,29,121.10
37.30
#1 58,220.10
6.38
#1 11,565
25.80
44.37
6,576.50
1,74,585.40
67.97
10,560.00
8.73
2,520
13.44
46.75
4,368.50
1,47,849.90
69.16
13,886.20
20.34
2,138
-26.91
50.11
1,375.20
1,11,086.00
28.76
27,711.70
-2.46
3,783
-55.32
52.65
1,076.60
1,08,331.20
21.14
26,719.70
13.65
5,242
7.82
68.91
1,263.30
1,05,440.50
25.35
33,593.30
-0.44
3,998
-86.05
41.47
2,261.20
1,03,346.60
#1 19.30
27,487.50
19.98
5,345
#1 87.72
45.17
2,369.50
97,814.20
50.52
14,277.60
12.03
1,750
31.75
50.42
1,440.40
83,658.70
23.88
33,384.70
3.21
3,376
1.99
48.90
1,394.30
75,272.20
84.57
6,812.90
#1 21.03
884
21.18
76.00
Growth Rate
Revenue Growth
35.32 %
Net Income Growth
75.04 %
Cash Flow Change
657.64 %
ROE
5.08 %
ROCE
39.15 %
EBITDA Margin (Avg.)
9.92 %

Quarterly Financial Results

Quarterly Financials
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
317
299
314
358
353
413
479
517
Expenses
257
234
244
286
273
318
367
395
EBITDA
61
64
70
73
80
95
112
121
Operating Profit %
19 %
21 %
22 %
20 %
22 %
23 %
23 %
23 %
Depreciation
9
8
9
10
10
12
12
12
Interest
10
7
8
12
11
11
10
10
Profit Before Tax
41
49
53
51
60
72
91
99
Tax
16
15
15
15
16
18
18
22
Net Profit
26
35
38
36
43
54
73
77
EPS in ₹
1.66
2.27
2.50
2.37
2.81
3.49
4.46
4.68

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
2026
Total Assets
430
538
560
750
1,110
1,451
2,327
Fixed Assets
157
188
193
199
307
327
519
Current Assets
265
340
328
502
763
1,063
1,682
Capital Work in Progress
2
6
3
25
10
7
41
Investments
19
14
0
0
0
0
729
Other Assets
252
331
364
526
793
1,118
0
Total Equity & Liabilities
430
538
560
750
1,110
1,451
2,327
Current Liabilities
78
111
184
361
573
786
836
Non Current Liabilities
12
53
71
102
152
124
202
Total Equity
341
374
305
286
385
541
1,289
Reserve & Surplus
335
369
300
281
370
526
1,272
Share Capital
5
5
5
5
15
15
17

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
1
67
-46
16
-4
54
Investing Activities
-84
-46
-46
-32
-68
-65
Operating Activities
6
62
-63
-75
21
159
Financing Activities
80
52
63
123
44
-40

Share Holding

% Holding
Jul 2024
Sept 2025
Oct 2025
Dec 2025
Mar 2026
Promoter
84.15 %
59.99 %
59.99 %
59.99 %
59.86 %
FIIs
0.00 %
9.37 %
9.37 %
7.99 %
7.54 %
DIIs
0.00 %
10.54 %
10.54 %
9.45 %
10.02 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
18.28 %
18.28 %
2.71 %
2.82 %
Others
15.85 %
1.82 %
1.82 %
19.86 %
19.76 %
No of Share Holders
15
1,05,311
1,05,311
31,914
33,738

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2025 638.50 627.25
03 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
03 Feb 2026 650.05 688.90
29 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 May 2026 969.10 967.90

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call Transcript1 day ago
Earnings Call Audio Recording4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS5 days ago
Compliances-Reg.24(A)-Annual Secretarial Compliance5 days ago
Statement On Deviation/Variation Of Funds And Further Extension Of Timeline For Utilization Of IPO Proceeds.5 days ago
Corporate Action-Board approves Dividend5 days ago
Formulation And Adoption Of New Employee Benefit Plan5 days ago
Audited Financial Results For The Quarter And Year Ended 31 March 2026 And Recommendation Of Dividend5 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation5 days ago
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31 2026 And Recommendation Of Dividend5 days ago
Earnings Conference Call9 days ago
Board Meeting Intimation for Intimation Of Board MeetingMay 22, 2026
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - Completion Of Acquisition Of Securities In Arinna Lifesciences LimitedApr 30, 2026
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 27, 2026
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Outcome Of USFDA Inspection At The CompanyS R&D Facility In CanadaApr 24, 2026
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Outcome Of USFDA Inspection At The CompanyS R&D Facility In CanadaApr 24, 2026
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 22, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 15, 2026
Announcement under Regulation 30 (LODR)-AcquisitionApr 15, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 13, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 31, 2026
Closure of Trading WindowMar 31, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 16, 2026
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 16, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 16, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 13, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 06, 2026
Newspaper Publication - Financial ResultsFeb 05, 2026
General UpdatesFeb 03, 2026
Announcement Under Regulation 30 - Appointment Of Secretarial AuditorFeb 03, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2026
Announcement under Regulation 30 (LODR)-Resignation of DirectorFeb 03, 2026
Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday February 03 2026Feb 03, 2026
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 03, 2026
Results - Financial Results For 31-12-2025Feb 03, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2026
Intimation Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 30, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 28, 2026
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Will Be Held On Tuesday 03Rd February 2026 Inter-Alia To Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 3Jan 27, 2026
Announcement under Regulation 30 (LODR)-AcquisitionJan 14, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJan 09, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015Jan 06, 2026
Closure of Trading WindowDec 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportDec 08, 2025
Intimation For Updation Of Corporate Identification Number ("CIN") Of The CompanyNov 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 18, 2025
Newspaper Publication - Financial ResultsNov 14, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
JioBlackRock Flexi Cap Fund Direct-Growth
0.12%
38621
0.12%
0.12%
TRUSTMF Mid Cap Fund Direct-Growth
0.98%
19263
0.98%
0.98%
Canara Robeco Manufacturing Fund Direct-Growth
2.25%
0
0.00%
0.20%
Kotak Midcap Fund Direct-Growth
0.58%
0
0.00%
0.05%
Bajaj Finserv Multi Asset Allocation Fund Direct-Growth
1.02%
0
0.00%
0.14%
Bajaj Finserv Small Cap Fund Direct-Growth
3.37%
0
0.03%
0.32%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.17%
0
0.00%
0.02%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.01%
0
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct-Growth
0.01%
0
0.00%
0.00%
Edelweiss Recently Listed IPO Fund Direct-Growth
1.85%
0
0.00%
0.08%
Kotak Manufacture in India Fund Direct-Growth
3.03%
0
0.00%
0.37%
HDFC Business Cycle Fund Direct-Growth
0.00%
0
0.00%
0.00%
HDFC Innovation Fund Direct-Growth
1.82%
0
0.21%
0.32%
HDFC Pharma And Healthcare Fund Direct-Growth
1.43%
0
0.00%
0.19%
ICICI Prudential Exports and Services Fund Direct-Growth
0.97%
0
0.00%
0.13%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Healthcare Fund Direct-Growth
4.48%
0
0.00%
0.64%
Bajaj Finserv Flexi Cap Fund Direct-Growth
1.34%
0
0.00%
0.11%
Groww Nifty Total Market Index Fund Direct-Growth
0.01%
0
0.00%
0.00%
Kotak Healthcare Fund Direct-Growth
1.96%
0
0.00%
0.21%
Mirae Asset Healthcare Fund Direct-Growth
0.10%
0
0.00%
-0.75%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.01%
0
0.00%
0.00%
Motilal Oswal Focused Fund Direct-Growth
3.10%
0
0.00%
3.10%
Motilal Oswal Nifty Microcap 250 Index Fund Direct-Growth
0.27%
0
0.00%
0.00%
Motilal Oswal Small Cap Fund Direct-Growth
3.83%
0
0.00%
0.05%

Technical Indicators

RSI(14)
Overbought
84.21
ATR(14)
Volatile
58.61
STOCH(9,6)
Neutral
59.73
STOCH RSI(14)
Overbought
91.65
MACD(12,26)
Bullish
24.01
ADX(14)
Strong Trend
48.06
UO(9)
Bearish
63.72
ROC(12)
Uptrend And Accelerating
36.21
WillR(14)
Overbought
-15.25